9月4日，第十七届中国生物产业大会在汉开幕。本届大会由中国生物工程学会等17家国家级学（协）会与中国科学报社共同主办，是 我国生物产业领域规模最大、影响最广的大型专业活动。 在光谷科技会展中心，大会集中展出了国内外生物产业基地、科研机构及龙头企业的最新成果，多项源自武汉、技术领先乃至"全球首 个"的重大创新产品集中亮相。 武汉禾元生物科技股份有限公司（以下简称"禾元生物"）展出了全球首创的植物源重组人血清白蛋白注射液奥福民®。一周多前，作 为全球首个"稻米造血"一类新药，该药品正式用于患者治疗，改写了人血清白蛋白依赖血浆提取的历史。 同济医院展示的光学脑机接口，在全球首创融合脑电图和近红外光谱多模态传感系统，主要用于脑出血康复，预计明年可上市。 中国生物产业大会现场。主办方供图 会上发布的《中国生物经济发展报告2025》显示，我国生物经济产业规模稳居全球第一，并呈现持续增长态势，在生物药在研品种、 脑机接口、高精度数字切片等前沿领域已实现"并跑"甚至"领跑"。 武汉自2018年起成为中国生物产业大会永久举办地之一。目前，武汉已形成覆盖创新研发、规模生产、临床运用全链条的生物医药产 业集群，产业规模突破5500 ...

Core Insights - The 17th China Bio-Industry Conference opened on September 4, focusing on "Biotechnology Empowering the Future, Biomanufacturing Reshaping the World" with an emphasis on "high-end, professional, international, and market-oriented" approaches [1] Group 1: Event Overview - The conference showcased numerous well-known companies presenting cutting-edge technologies, products, and applications, highlighting the latest advancements in the global bio-industry [1] Group 2: Exhibitor Highlights - BGI Genomics displayed tissue slices applied in spatiotemporal chips [3] - The Optics Brain-Computer Interface and near-infrared brain function imaging device from the Optics Valley Biocity exhibition area attracted significant attention from foreign guests [4] - United Imaging Healthcare presented a 5T magnetic resonance imaging system [6] - Heyuan Bio showcased recombinant human albumin injection (from rice) [7]

Core Insights - China has become the second largest biopharmaceutical market globally, meeting domestic demand while gradually participating in international market competition [1] - The report highlights China's leading position in areas such as research and development of biopharmaceuticals, brain-computer interfaces, and high-precision digital slicing [1] Industry Developments - In 2024, the National Medical Products Administration of China approved 93 new drugs, marking a five-year high, with China ranking second globally in the number of drugs under research [2] - Four Chinese companies made it to the top 25 global pharmaceutical companies in terms of R&D pipeline scale, setting a new historical record [2] - China published over 20,000 SCI papers in the medical equipment field in 2024, leading the world in research output [2] - The biopharmaceutical industry in China accounts for over 30% of global innovative drugs, research pipelines, and newly listed drugs [2] Economic Impact - The value of bio-based materials and chemicals has surpassed 1 trillion yuan, with the contribution of the bio-economy to GDP exceeding 7% [2] - China has established 23 biopharmaceutical industry bases, leading globally in the number of biotechnology patent applications and R&D personnel [2] International Collaboration - The conference attracted Cuba's largest state-owned pharmaceutical group, highlighting successful collaboration in biotechnology between China and Cuba [3] - Jointly developed drugs, such as the EGFR monoclonal antibody for cancer treatment, have benefited over 50,000 Chinese patients [3]

Group 1 - The 17th China Bio-Industry Conference highlighted that China has become the second-largest biopharmaceutical market globally, meeting domestic demand while gradually participating in international market competition [1] - The report indicates that China is in a leading position in areas such as biopharmaceuticals under research, brain-machine interfaces, and high-precision digital slicing [1] - The global focus on biomanufacturing and circular economy strategies is increasing, with significant funding for gene and cell engineering research, biomass utilization, and the development of bioproducts [1] Group 2 - In 2024, China approved 93 new drugs, the highest in five years, and ranks second globally in the number of drugs under research [2] - Four Chinese companies made it to the top 25 global pharmaceutical companies in terms of R&D pipeline scale, marking a historic achievement [2] - China leads the world in the number of SCI papers published in medical equipment, with over 20,000 papers in 2024, showcasing strong research resources and innovation capabilities [2] Group 3 - The National Development and Reform Commission reported that China has established 23 biomanufacturing bases, leading in biotechnology patent applications and R&D personnel [2] - The biopharmaceutical industry in China ranks second globally, with innovative drugs, research pipelines, and newly approved drugs accounting for over 30% of the global total [2] - The value of biobased materials and chemicals has surpassed 1 trillion yuan, with the contribution of the bio-economy to GDP exceeding 7% [2] Group 4 - The conference featured over 200 renowned institutions and companies, showcasing more than 1,000 products, including several global firsts [2] - Notable innovations included a multimodal sensing system for brain rehabilitation and a world-first 5.0T whole-body MRI system [3] - The collaboration between China and Cuba in biotechnology was highlighted as a successful partnership, with joint research and production benefiting both nations [3]